First Insight on Small Molecules as Cardiac Calsequestrin Stabilizers

Area of Science:

• Biochemistry
• Pharmacology
• Cardiology

Background:

• Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic heart rhythm disorder.
• CPVT arises from mutations in cardiac calsequestrin (CASQ2), disrupting its calcium (Ca2+)-induced polymerization-depolymerization.
• Pharmacological stabilization of CASQ2 polymers for CPVT treatment remains unexplored.

Purpose of the Study:

• To investigate small molecules for their ability to stabilize CASQ2 polymers.
• To identify potential therapeutic agents for CPVT by targeting CASQ2 function.

Main Methods:

• Synthesis of 24 glycinate/alaninate/acetate α-pyranone analogs.
• Assessment of CASQ2 depolymerization inhibition using a Ca2+ chelation assay.
• Structure-activity relationship analysis of synthesized compounds.

Main Results:

• Most synthesized α-pyranone analogs inhibited CASQ2 depolymerization.
• Compounds featuring a 4-fluoro-phenyl group at C-6 and an open-chain primary amine at C-4 demonstrated the highest activity.
• This study presents the first α-pyranone compounds capable of stabilizing CASQ2 polymers.

Conclusions:

• The identified α-pyranone analogs can stabilize CASQ2 polymers.
• This discovery opens avenues for developing treatments for Ca2+-release disorders by modulating CASQ2 polymerization.
• This represents a novel therapeutic approach for CPVT and related conditions.